DiOHF (3 ,4 -dihydroxyflavonol) is cardioprotective against I/R (ischaemia/reperfusion) injury. The biological activities of flavonols are associated with kinase modulation to alter cell signalling. We thus investigated the effects of DiOHF on the activation of MAPKs (mitogen-activated protein kinases) that regulate the cardiac stress response. In an ovine model of I/R, JNK (c-Jun N-terminal kinase), p38
MAPK , ERK (extracellularsignal-regulated kinase) and Akt were activated, and NP202, a pro-drug of DiOHF, reduced infarct size and inhibited JNK and p38 MAPK activation, whereas ERK and Akt phosphorylation were unaltered. Similarly, in cultured myoblasts, DiOHF pre-treatment preserved viability and inhibited activation of JNK and p38
MAPK , but not ERK in response to acute oxidative and chemotoxic stress. Furthermore, DiOHF prevented stress-activation of the direct upstream regulators MKK4/7 (MAPK kinase 4/7) and MKK3/6 respectively. We utilized small-molecule affinity purification and identified CaMKII (Ca 2 + /calmodulin-dependent protein kinase II) as a kinase targeted by DiOHF and demonstrated potent CaMKII inhibition by DiOHF in vitro. Moreover, the specific inhibition of CaMKII with KN-93, but not KN-92, prevented oxidative stress-induced activation of JNK and p38
MAPK . The present study indicates DiOHF inhibition of CaMKII and attenuation of MKK3/6→p38
MAPK and MKK4/7→JNK signalling as a requirement for the protective effects of DiOHF against stress stimuli and myocardial I/R injury.
INTRODUCTION
Myocardial I/R (ischaemia/reperfusion) injury and associated cardiac myocyte loss follow the restoration of blood flow and reoxygenation post-ischaemia. These processes are mediated by mechanisms including increased ROS (reactive oxygen species), restoration of physiological pH, influx of Ca 2 + and increased inflammatory factors, which together induce apoptosis that contributes to the final myocardial infarct size [1] . Although pharmacological interventions to limit I/R injury would be of clear therapeutic benefit, there are currently no drugs approved for clinical use. In previous studies we reported that the synthetic flavonol DiOHF (3 ,4 -dihydroxyflavonol) substantially reduced cardiac I/R injury in a clinically relevant large animal model [2] [3] [4] . Importantly, DiOHF treatment conferred a similar degree of protection to ischaemic pre-conditioning [3] . Furthermore, the protective and functional benefits from DiOHF treatment were sustained over the long term [4] . These studies highlight the potential of DiOHF as a therapeutic to reduce I/R injury.
DiOHF is a synthetic analogue of a group of naturally occurring phenolic compounds known as flavonols. The mechanisms underlying cardioprotection by DiOHF could be attributed to its antioxidant, vasorelaxant and anti-inflammatory actions [5] . More recently, we demonstrated that DiOHF treatment in a sheep model of cardiac I/R injury was accompanied by blunted activation of p38 MAPK (mitogen-activated protein kinase) [2] , suggesting that DiOHF affects intracellular signalling pathways regulated by protein kinases and that this may contribute to its cardioprotective properties.
The best-characterized MAPK family members, ERK (extracellular-signal-regulated kinase), JNK (c-Jun N-terminal kinase) and p38 MAPK , are considered amongst the key mediators of many intracellular signal transduction events in cardiac myocytes [6, 7] . Each MAPK is activated by phosphorylation by specific upstream MKKs (MAPK kinases) as part of a three-tiered cascade of kinases [MAPKKK (MKK kinase)→MKK→MAPK] in response to a wide range of physiological and pathological stimuli [8] . Although the diverse regulation of upstream MAPKKKs and the integration of downstream components into distinct signalling events is thought to confer signalling specificity and the co-regulation of the MAPK activation with other signalling events [8, 9] , the actions of the active MAPKs on their large repertoire of downstream substrates leads to complex functional consequences including cell growth, differentiation and survival [10] [11] [12] . Although all three MAPK family members (ERK, JNK and p38 MAPK ) can be activated in response to I/R, their precise contributions to cardiac injury remain a subject of intense debate (reviewed in [7] ).
Studies on the function of MAPK family members in isolated cardiac myocytes or animal models of I/R injury have generally reported protective functions for ERK signalling and detrimental consequences of excessive p38 MAPK and JNK activation [7, 13] . ERK activation, along with PI3K (phosphoinositide 3-kinase)/Akt signalling, represents a major component of the RISK (reperfusion injury salvage kinase) pathway that promotes cardiomyocyte survival and cardioprotection [13] . In contrast, the consequences of activated p38 MAPK and JNK, also referred to collectively as SAPKs (stress-activated protein kinases), are more complex. Studies that have utilized kinase-specific small molecule inhibitors or dominant-negative mutants have revealed that p38 MAPK and JNK activation promotes myocardial cell death [14] [15] [16] . Yet others have reported disparate findings on p38 MAPK and JNK contributions during I/R [17] [18] [19] . For example, genetic activation of JNK prevented cell death induced by myocardial I/R in vivo [17] , whereas another report found no cardioprotective effects from the administration of p38
MAPK selective inhibitors in a large animal model of I/R injury [18] . Moreover, p38 MAPK and JNK activation during ischaemic pre-conditioning may paradoxically promote cardioprotective effects [20] . The lack of consensus in MAPK function is similarly reflected for other cardiac pathologies [7] . Thus the functional consequence of MAPK activation in the context of myocardial I/R is complex and reasons for the contradictory findings are undefined.
The characterization of signalling mechanisms responsible for the stress-induced activation and detrimental actions of MAPK isoforms may provide clarification on MAPK function during I/R. ASK1 (apoptosis signal-regulated kinase 1) and CaMKII (Ca 2 + /calmodulin-dependent protein kinase II) are examples of upstream kinases that are known to signal to JNK and/or p38 MAPK isoforms [21, 22] , respond to Ca 2 + influx and increased ROS [23] and their inhibition reduces myocardial cell death and I/R injury [24] [25] [26] . However, the pathophysiological functions of these proximal kinases are mediated through multiple mechanisms and the contributions of downstream MAPK activation are not fully defined.
In a clinically relevant large animal model, we sought to define the temporal changes in the signalling mechanisms that mediate myocardial I/R injury and determined the actions of the cardioprotective flavonol DiOHF on these changes. These findings were further validated in more homogenous in vitro cultures of myoblasts and cardiac myocytes. To identify the direct intracellular targets of DiOHF we utilized small-molecule affinity pull-down. In addition to understanding the mechanism of action of DiOHF, these studies provide insights into the critical molecular events underlying I/R injury.
EXPERIMENTAL

Reagents and antibodies
DiOHF was purchased from Indofine. Adipate modified water soluble DiOHF (NP202) and HF (hydroxyflavonol) was synthesized using established schemes as previously described [27] [28] [29] . Immobilized DiOHF was generated by cross-linking DiOHF-6-succinimic acid [29] 
Myocardial I/R injury in sheep
Studies were performed on adult merino ewes (35-45 kg) that were randomly assigned to a treatment protocol. All experiments were approved by the Animal Ethics Committee of the Florey Institute of Neuroscience and Mental Health under guidelines laid down by the National Health and Medical Research Council of Australia. In anaesthetized ewes, surgical ligation of the second diagonal branch of the left anterior descending coronary artery (D2) was performed as described previously [2] . Ischaemia (1 h) was induced by occluding the D2 with a vascular snare, and reperfusion was achieved by releasing the snare. Arrhythmias were managed by administration of lignocaine into the left atrium. NP202 (6.6 mg/kg), a water-soluble analogue of DiOHF, or vehicle (10 ml of 0.1 M Na 2 CO 3 ) were administered intravenously via a jugular vein catheter at 5 min before reperfusion in the different treatment groups (10, 30, 60 or 180 min). Sheep were randomized to five groups that were killed with an intravenous overdose of pentobarbitone (100 mg/kg) at 0, 10, 30, 60 or 180 min of reperfusion (n = 6 per group).
After reperfusion, the AAR (area-at-risk) was determined by re-occluding the D2 before Evans Blue dye (1.5 %, 40 ml) was injected into the left atrium simultaneously with intravenous pentobarbitone (100 mg/kg). The heart was excised, the left ventricle cut into 1 cm transverse rings, which were photographed to outline the AAR. The rings were then immersed in TTC (triphenyltetrazolium chloride), which has been shown to reliably indicate early-phase acute myocardial infarct size [30] . Viable tissue was stained with TTC, and the rings were re-photographed. Computerized planimetry (MCID TM M2) was used to measure the area of unstained infarct tissue relative to AAR. Tissue from the non-infarcted AAR was dissected from the myocardial rings for protein extraction for immunoblot analysis [2] . In brief, noninfarcted AAR samples were snap-frozen in liquid nitrogen, ground into a fine powder, and subsequently lysed with ice-cold RIPA buffer in a 5:1 (w/v) ratio for immunoblot analysis.
Cell culture and treatments
Murine skeletal myoblasts (C2C12) or rat cardiac myoblasts (H9C2) were maintained in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10 % (v/v) fetal bovine serum and 100 units/ml penicillin/streptomycin. Cells were incubated overnight at 37
• C in a 5 % CO 2 incubator before the experiment. Cells were pre-treated with flavonols or DMSO (0.1 %) as a vehicle control for 30 min before stress treatments. Following pretreatment, cells were stimulated by the addition of H 2 O 2 (1 mM), sorbitol (0.5 M) or arsenite (300 μM). Following treatment, cells were assessed for viability or protein lysates prepared for immunoblot analysis.
Identification of cellular targets of DiOHF
CarboxyLink DADPA (diamino-dipropylamine)-activated crosslinked 4 % beaded agarose resin (16 μmol of amine per ml of gel, Thermo Scientific) was coupled with 10 mol of 6-(hydroxycarbonylethylcarbonylamino)flavonol [29] (to afford agarose-HF beads) or 3 ,4 -dihydroxy-6-(hydroxycarbonylethylcarbonylamino)flavonol [29] (to afford agarose-DiOHF beads) and 10 mol of EDC [N-ethyl-N'-(3-dimethylaminopropyl)carbodi-imide] per amine equivalent in 0.1 M Mes buffer at pH 4.7 containing 85 % DMF (dimethylformamide). The reaction mixture was mixed by tumbling at room temperature (20 • C) or 40
• C respectively and allowed to react overnight. Resin was filtered and washed with 75 % Mes/DMF and then 100 % DMF to remove excess reagents. The resin was then washed with 100 % Mes buffer and stored in Mes buffer containing 0.02 % NaN 3 at 4
• C. The effectiveness of the coupling reactions were assessed using a phenol spot test [aq. DiOHF-agarose was incubated with whole-cell protein lysates (10 mg) prepared from C2C12 myoblasts and mixed with end-over-end rotation overnight at 4
• C. The bound protein fraction was isolated by pelleting DiOHF-agarose followed by repeated washes with lysis buffer. Isolated proteins were then eluted with free DiOHF, resolved by SDS/PAGE (12 %) and proteins were visualized with GelCode Blue Stain (Thermo Scientific). As a control, an identical pull-down was performed with agarose beads only. Protein bands isolated by DiOHF-agarose were excised, de-stained with ammonium bicarbonate in 50 % acetonitrile, reduced in-gel by TCEP [tris-(2-carboxyethyl)phosphine] solution (Sigma-Aldrich), and subsequently alkylated with 100 mM idoacetamide. In-gel tryptic digest was carried out with 12.5 ng/ml trypsin solution in 25 mM ammonium bicarbonate at 4
• C for 30 min, before overnight incubation at 37
• C. LC-MS/MS was performed on a CID (collision-induced dissociation) Ion Trap (Agilent) equipped with a HPLC nanochip. The resultant MS/MS data were analysed by interrogation against the SwissProt Mus musculus database in Mascot (Matrix Science). Parameters used for the search are as follows: up to two trypsin missed cleavages allowed; carbamidomethyl of cysteine residue and oxidation of methionine residue as fixed and optional modification respectively; and peptide mass tolerance of 0.6 Da. A false discovery rate threshold of 1 % and expect value of <0.05 for significant peptide matches were applied to exclude false positives. In addition, hits had to be common among three separate experiments in ordered to be considered.
In vitro ADP-Glo TM CaMKII phosphorylation assay
Active CaMKIIδ (50 ng, Merck Millipore) was incubated with autocamtide-2 peptide substrate (KKALRRQETVDAL, 5 μg) in a reaction buffer containing 40 mM Tris/HCl, pH 7.5, 20 mM MgCl 2 , 0.1 mg/ml BSA, 0.4 mM CaCl 2 , 1 mg/ml calmodulin and 0.5 mM DTT. Kinase reactions were initiated by the addition of ATP (50 μM) to a final reaction volume of 25 μl and incubated for 15 min at 30 • C. Reactions were terminated and surplus ATP depleted by the addition of ADP-Glo TM reagent (25 μl, Promega) and incubated for a further 40 min at room temperature. Kinase Detection Reagent containing luciferase was then added (50 μl for 30 min at room temperature) and luminescent signals measured on a POLARStar Optima microtitre platereader (BMG Labtech) to report on ADP levels and kinase activity. An ATP/ADP standard curve absent kinase and substrates was prepared and measured simultaneously to allow extrapolation of ADP concentrations. KN-93, a specific CaMKII inhibitor, and DiOHF were pre-incubated with CaMKIIδ before the addition of calmodulin and peptide substrates.
XTT cell viability assay
Cell proliferation was determined by labelling cells with the yellow tetrazolium salt XTT {sodium 3 -[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate}, using the XTT Cell Proliferation Kit (Roche Applied Science) according to the manufacturer's specifications. Briefly, cells (2×10 5 /well) were seeded on to a 96-well plate. Following cell treatments, the XTT labelling reagent was added during the final 2 h then the attenuance was measured at 492 nm to indicate cell numbers and attenuance readings at 690 nm used as a reference (D 492 -D 690 ). Background absorbance (XTT reagent incubated in the absence of cells) was subtracted from all values and cell viability determined by dividing flavonol and stresstreated values by vehicle control.
LDH (lactate dehydrogenase) cell survival assay
Cells (0.5×10 5 /well) were seeded on to a 96-well plate. Following cell treatment, the cellular release of LDH was determined by measuring LDH activity in conditioned medium using a cytotoxicity detection kit (LDH Release Assay, Roche Applied Science). In brief, at the end of the treatment period, supernatants (50 μl) were transferred on to a new plate and a tetrazolium salt INT (2-p-iodophenyl-3-p-nitrophenyl-5-phenyl tetrazolium chloride) mixture (50 μl/well) was added and incubated under low light for 30 min before measuring attenuance (490 nm, reference wavelength 650 nm). Maximum LDH release was achieved by the addition of 1 % (w/v) Triton X-100. Percentage LDH release was determined from the ratio of sample D /maximum LDH release D .
Cell lysate preparation and immunoblotting
Cell lysates were prepared in RIPA buffer [50 mM Tris/HCl, pH 7.3, 150 mM NaCl, 0.1 mM EDTA, 1 % (w/v) sodium deoxycholate, 1 % (v/v) Triton X-100, 0.2 % (w/v) NaF and 100 μM Na 3 VO 4 ] supplemented with protease inhibitors [31] . After 10 min on ice, cell debris was removed by centrifugation (14 000 g, 10 min). Protein concentrations were then determined by Bradford assay. Protein lysates were resolved by SDS/PAGE, transferred on to polyvinylidene fluoride membranes, blocked with 5 % (w/v) non-fat dried skimmed milk powder in TBST (10 mM Tris, pH 7.5, 150 mM NaCl and 0.1 % Tween 20) and then blotted with primary antibodies (1/250 to 1/1000 dilution, depending on the antibody and determined experimentally) in the block solution. Horseradish peroxidase-conjugated secondary antibodies were diluted 1/20 000 in 1 % (w/v) non-fat milk powder in TBST. ECL detection was with SuperSignal West Pico (PIERCE) or Lumi-Light Plus (Roche) according to the manufacturers' instructions. Chemiluminescence was imaged on a Chemidoc MP system (Bio-Rad Laboratories) and densitometric band quantitation performed using ImageJ (NIH).
Statistical analysis
All values are presented as means + − S.E.M. Data were analysed with SigmaStat (version 2.03, SPSS). Groups were compared using two-way ANOVA or unpaired Student's t tests as appropriate. P values <0.05 were considered significant.
RESULTS
NP202 reduced infarct size in sheep following I/R
In anaesthetized sheep, following 1 h of myocardial ischaemia there were progressive increases in infarct size as the length of reperfusion increased. After reperfusion for 30 min, 1 h and 3 h, infarct sizes were 57 + − 3, 66 + − 6 and 78 + − 6 % of the AAR respectively ( Figure 1A ). Treatment with NP202 (6.6 mg/kg), administered 5 min before reperfusion, significantly reduced infarct size 15 + − 1, 33 + − 1 and 40 + − 2 % at 30 min, 1 h and 3 h of reperfusion respectively ( Figure 1A ). These findings demonstrate the potent cardioprotective effects of DiOHF against a 1 h ischaemia and a range of reperfusion times.
Kinase phosphorylation changes in a sheep model of myocardial I/R
It has been proposed that following I/R, decisions regarding cell survival or death are dependent on the relative activation of myocardial JNK, p38
MAPK , ERK and Akt. In particular, the activities of these kinases in the salvageable non-infarcted AAR are likely to be important determinants of the final infarct size [32] . To assess whether there are temporal changes in the activation of these kinases following reperfusion, we assessed their phosphorylation status as an indication of activation at 0, 10, 30 and 60 min of reperfusion. Importantly, all measurements were made on tissue from the non-infarcted AAR, the area that can be salvaged by cardioprotective treatments. Increased kinase phosphorylation was observed from 10 min of reperfusion and peaked at 30 min. For the stress-activated kinases p38 MAPK and JNK their phosphorylation at 30 min was increased 5.8-fold and 6.2-fold respectively, over the levels at the end of ischaemia, before decreasing by a 1 h reperfusion (Figures 1B and 1C). Similarly, phosphorylation of ERK and Akt peaked at 11.7-fold and 11.9-fold by 30 min of reperfusion respectively, before trending towards basal levels at 1 h of reperfusion ( Figures 1D  and 1E ). Our blots also revealed inter-individual variability in SAPK activation (see Figure 1F ) that may reflect the genetic heterogeneity within Australian domestic sheep populations [33] . Taken together, these findings highlight the rapid activation of p38 MAPK , JNK and ERK as well as Akt in the AAR region following reperfusion.
NP202 attenuated p38
MAPK and JNK phosphorylation in sheep
To examine the impact of NP202 treatment on MAPK and Akt activation in response to I/R, we determined its effect on their activation at the time of peak phosphorylation (i.e. at 30 min reperfusion). Myocardial p38 MAPK and JNK phosphorylation levels in the non-infarcted AAR region were significantly lower in sheep pre-treated with NP202, than the equivalent vehiclepre-treated animals (Figures 2A and 2B) . In contrast, ERK and Akt phosphorylation levels were not significantly altered in the presence of NP202 (Figures 2C and 2D) . Thus our studies in this large animal model of acute myocardial I/R reveal that administration of NP202 in vivo inhibited p38 MAPK and JNK activation at 30 min reperfusion which was associated with a significant reduction in infarct size (Figures 1 and 2) . Furthermore, these in vivo findings are entirely consistent with our observations of the effect of DiOHF on kinase activation profiles in cultured cells, and suggest that flavonol inhibition of SAPK, but not RISK pathways, contributes to the cardioprotection.
DiOHF is cytoprotective against oxidative and chemical stress stimuli
To define the protective and kinase modulatory properties of DiOHF, we evaluated its effects in greater detail in vitro. We evaluated the protection of C2C12 murine myoblasts against detrimental stress stimuli using an XTT assay of cell viability. In a time-course of oxidative damage, we observed that 2 h treatment with H 2 O 2 (0.5 or 1.0 mM) reduced myoblast viability to 38.5 + − 2.0 and 32 + − 0.8 % respectively ( Figure 3A) . Pretreatment with DiOHF (10 μM) significantly improved the viability of C2C12 cells challenged with H 2 O 2 ( Figure 3B ). Stress-stimulated cell membrane permeability and cell death was assessed by LDH activity assays and this confirmed that We then explored the effects of DiOHF on cell death induced by arsenite, a chemical toxin that induces cell death through p38 MAPK and JNK activation [34, 35] . In time course and doseresponse studies, we found that C2C12 viability was substantially reduced by arsenite treatment ( Figure 3D ). Pre-treatment with DiOHF (10 μM) significantly reduced arsenite-induced cell loss, with 67 + − 5 % of cells remaining viable compared with 27 + − 4 % viability when cells were pre-treated with vehicle (DMSO) ( Figure 3E ). These data revealed the beneficial protective effects of DiOHF treatment against both H 2 O 2 and arsenite stress stimulation in cultured and isolated cells.
DiOHF inhibited JNK and p38 MAPK pathway activation by H 2 O 2 and arsenite
We next evaluated whether activation of SAPKs by stress in murine myoblasts was inhibited by DiOHF pre-treatment. Both H 2 O 2 -and arsenite-stimulated increases in p38
MAPK and JNK phosphorylation in murine myoblasts were significantly inhibited by DiOHF pre-treatment ( Figures 4A and 4B) . Similarly, we confirmed that DiOHF pre-treatment inhibited stress-stimulated p38 MAPK and JNK activation in primary cardiac myocytes (Supplementary Figure S2 at http://www.biochemj.org/bj/456/ bj4560149add.htm). In contrast, DiOHF pre-treatment did not reduce stress-stimulated ERK phosphorylation ( Figure 4C ). In addition, we observed that DiOHF blocked p38 MAPK and JNK phosphorylation in cardiac myocytes exposed to hyperosmolarity with sorbitol treatment (results not shown). Thus our results indicate DiOHF inhibition of the SAPKs against a broad range of distinct stress stimuli.
In considering the impact of DiOHF on signalling events both upstream and downstream of the MAPKs, we showed that phosphorylation of the direct downstream targets of p38 MAPK and JNK, MAPKAP-K2 and c-Jun, was also decreased following DiOHF pre-treatment before stress treatment of myoblasts ( Figures 5A and 5B) . Furthermore, arsenite stimulated potent phosphorylation of MKK3/6, MKK4 and MKK7 and each was substantially inhibited by DiOHF pre-treatment (Figures 5C-5E). In contrast, H 2 O 2 treatment did not induce detectable increases in MKK3/6 or MKK4 phosphorylation ( Figures 5C and  5D ). However, H 2 O 2 -stimulated phosphorylation of MKK7 was inhibited by DiOHF pre-treatment ( Figure 5E ). Collectively, our studies indicate the impact of DiOHF on signalling events, leading to attenuated activation of both the p38 MAPK and JNK pathways. 
DiOHF modulation of p38 MAPK and JNK signalling requires 3 -and 4 -hydroxyl groups
Previous studies have shown that the number and position of hydroxyl groups on the B ring of flavonols are critical for the binding and inhibition of kinases [36] [37] [38] . To test requirements for the dihydroxylated catechol group on DiOHF for modulating signalling to SAPKs and cytoprotection, we evaluated the kinase modulating properties of HF (3-hydroxyflavone), a DiOHF analogue lacking the B ring 3 -OH and 4 -OH groups ( Figure 6A ). Whereas DiOHF pre-treatment inhibited H 2 O 2 or arsenite-stimulated p38 MAPK and JNK phosphorylation, HF pretreatment was much less effective at inhibiting stress-induced kinase phosphorylation (Figures 6B-6D ). More specifically, pre-treatment with HF, in contrast with DiOHF, did not prevent arsenite-stimulated p38 MAPK and JNK phosphorylation ( Figures 6B and 6C) . Similarly, HF pre-treatment did not inhibit H 2 O 2 -stimulated p38 MAPK phosphorylation, but maintained partial inhibition of H 2 O 2 -stimulated JNK phosphorylation ( Figures 6B and 6C) . In comparison, ERK phosphorylation was not markedly altered by stress-stimulation or flavonol pre-treatment ( Figure 6D) . Our results indicate a requirement for the 3 -OH and 4 -OH groups for DiOHF inhibition of p38 MAPK activation in response to detrimental stress stimuli. The requirement for both 3 -OH and 4 -OH groups of JNK inhibition was more stress-context dependent.
We then determined the cytoprotective properties of HF and DiOHF. In response to H 2 O 2 , cell viability was significantly increased with HF pre-treatment relative to DMSO control (44 + − 3 % viable cells compared with 27 + − 1 %, Figure 6E ). However, this was substantially lower compared with DiOHF treatment (65 + − 1 % viability) ( Figure 6E ). Notably, HF retained some inhibitory activity against H 2 O 2 -stimulated JNK phosphorylation ( Figure 6C ). In response to arsenite, HF pretreatment did not significantly improve cell viability when compared with DMSO controls ( Figure 6F ). Thus these studies reinforce a link between DiOHF-mediated cytoprotection and the dual-inhibition of p38 MAPK and JNK signalling.
DiOHF targets CaMKII
Conservation of the MAPK cascade diverges at the level of MAPKKK with multiple protein kinases capable of activating MKK4/7/JNK and MKK3/6/p38 MAPK pathways [10] . To define the mechanism of action of DiOHF, we utilized small molecule affinity purification to identify its cellular targets. Affinity pulldown of C2C12 whole-cell lysates with agarose immobilized DiOHF specifically isolated multiple proteins ( Figure 7A ) compared with a bead-only control. Through peptide mass fingerprinting using MS, we identified the most prominent protein band (∼52 kD) as CaMKIIδ ( Figure 7A ). Through an immunoblot analysis, we demonstrated that, in contrast with DiOHF, immobilized HF did not pull down CaMKII ( Figure 7B ). This indicated that CaMKII was a DiOHF-specific target. Indeed, DiOHF potently inhibited active CaMKIIδ in in vitro kinase assays ( Figure 7C) Figure 7D) . Lastly, H 2 O 2 -stimulated JNK and p38
MAPK phosphorylation was substantially inhibited by KN-93 pre-treatment ( Figure 7E ). This places CaMKII upstream of JNK and p38
MAPK in the context of oxidative stress and indicates that DiOHF inhibition of stress-stimulated JNK and p38 MAPK activation is mediated through direct targeting of CaMKII (Figure 8 ). This represents a novel mechanism of action of DiOHF. Future studies will determine the extent to which CaMKII inhibition contributes to the protective effects of DiOHF.
DISCUSSION
We have investigated the mechanisms of action of the cardioprotective effect of DiOHF, in both in vitro and in vivo model systems, by determining its actions on signalling pathways that determine the level of myocardial I/R injury [7, 13] . The studies in anaesthetized sheep indicate activation of both protective and detrimental kinases during reperfusion, with the infarct size and levels of the SAPKs being reduced by NP202, an analogue of DiOHF. Importantly, our in vitro studies revealed similar protective effects of DiOHF treatment on myoblasts and primary cardiac myocytes in culture, indicating that these systems can be used to investigate in further detail the mechanisms by which DiOHF induces cardioprotection in vivo.
The ability of treatment with DiOHF to decrease infarct area expansion in anaesthetized sheep was evident at 30 min of reperfusion and this correlated with peak activation of the MAPKs (ERK, JNK and p38 MAPK ) and Akt. The rapid and transient activation of ERK and Akt following reperfusion in sheep which was consistent with a previous study in a porcine model of myocardial I/R [40] . In addition, we observed similar kinetics in JNK and p38 MAPK activation and, as far as we are aware, the present study is the first to describe temporal changes in JNK and p38 MAPK activation in an ovine model of myocardial I/R. These intracellular signalling pathways have been implicated as critical regulators of myocardial injury and cardiomyocyte survival in response to I/R [7, 41] . Thus the effects of DiOHF on MAPK and Akt activation provides molecular insights into the signalling mechanisms critically involved in modulating myocardial I/R injury and information on the mechanisms of action of a promising cardioprotective compound.
There is increasing evidence that the biological activity of flavonols may be mediated through direct actions on intracellular signalling pathways. Naturally occurring flavonols have been shown to stimulate or inhibit activity of tyrosine kinases, PI3K/Akt, protein kinase C, protein kinase A and MAPKs, to exert beneficial effects in disease states including cardiovascular disease [42] . In addition, several flavonoid derivatives (e.g. PD8059 and LY294002) represent widely used research tools for delineating MAPK signalling functions in a variety of experimental models [43, 44] . The intracellular effects of DiOHF in other cellular systems include modulation of PDGF receptor autophosphorylation, FAK (focal adhesion kinase) and RhoA activity [45, 46] . In the present study, we demonstrated that in vivo activation of ERK and Akt in sheep following myocardial I/R heart was not altered by DiOHF. This may be biologically significant as attenuation of these prosurvival kinases has been shown to be detrimental during ischaemia [13] . In contrast, DiOHFinduced cardioprotection was accompanied by significantly reduced SAPKs activation in the salvageable ischaemic region (non-infarcted AAR). Furthermore, the cytoprotective and SAPK inhibitory effects were lost with a structural analogue of DiOHF (HF) lacking hydroxyl groups on the B ring. Previous structure activity relationship and crystallization studies have shown that the catechol group of flavonols determines the direct interaction with specific kinases [36, 37] . This suggests that JNK and p38 MAPK activation during I/R has detrimental actions, and attenuation of these pathways by DiOHF may contribute to the beneficial actions of the drug. Our findings support previous studies which have shown that selective inhibition of p38 MAPK or JNK reduced infarct size and cell death, consistent with the notion that activation of SAPKs promotes I/R injury [14, 16, 38, 47] . Our findings provide strong support for kinase inhibition contributing to the protective effects of DiOHF against acute stress stimuli.
As with many flavonols, DiOHF exhibits potent antioxidant activity which has been proposed to contribute to its cardioprotective effects [27, 29] . However, scavenging of reactive oxygen is unlikely to be the sole mechanism underlying DiOHF inhibition of SAPK signalling. First, the concentrations of H 2 O 2 (mM) are far in excess of the concentration of DiOHF (μM) so that DiOHF levels in the medium are unlikely to be sufficient to prevent H 2 O 2 activation of SAPKs through a direct scavenging activity. In support of this, a significantly higher concentration of N-acetylcysteine (10 mM), an antioxidant with no known direct kinase modulatory actions, was required to attenuate H 2 O 2 -stimulated JNK and p38 MAPK activation in our cultured cell models (results not shown). Secondly, DiOHF exhibited activity against a broad range of cellular stress, including hyperosmotic shock, which is not thought to directly contribute to free radical generation, and arsenite treatment, a cardiotoxic protein-damaging agent used to model stress signalling responses [48] [49] [50] . Arsenite treatment induces SAPK signalling through mechanisms that are independent of oxidative stress [51, 52] . Thus DiOHF inhibition of p38 MAPK and JNK activation in response to these diverse stress stimuli highlighted that kinase modulation by DiOHF was independent of its antioxidant status.
The concentrations of DiOHF utilized in the present study are, however, sufficient for kinase inhibition through direct interaction. Naturally occurring flavonols have been shown to modulate a wide range of intracellular signalling pathways [42] . This may be due to broad selectivity arising from targeting the ATP pocket that is highly conserved between kinase families although highly selective targeting of closely related kinases by ATP-competitive inhibitors can be achieved [53, 54] . An added complication is that the direct protein targets responsible for the intracellular signalling functions of many flavonols have not been fully elucidated. The present study indicates that DiOHF attenuation of stress-stimulated p38 MAPK and JNK signalling extends to the inhibition of phosphorylation of their direct upstream activating kinases, MKK3/6 and MKK4/7 respectively. This indicates that DiOHF affects signalling events upstream of MAPKKs that lead to JNK and p38 MAPK activation. In determining the intracellular targets of DiOHF, we identified CaMKII as a significant myocardial kinase directly inhibited by DiOHF and required for stress-induced JNK and p38 MAPK activation in cultured myoblasts.
CaMKII has well-documented pathophysiological functions in the heart with detrimental effects contributing to arrhythmia and heart failure [55, 56] . The CaMKII holoenzyme is activated by Ca 2 + /calmodulin binding at regulatory domains which triggers a conformational change that allows substrate access at the catalytic sites. Sustained increases in Ca 2 + and high levels of ROS results in CaMKII autophosphorylation and oxidation that renders the enzyme autonomous from canonical Ca 2 + /calmodulin regulation [39, 57] . CaMKII is activated in response to I/R and this exacerbates myocardial cell death that involves direct effects on mitochondrial membrane permeability transitions [58] . In addition, our study highlights stress-induced CaMKII signalling to SAPKs which is probably detrimental in the context of I/R.
We showed that specific inhibition of CaMKII with KN-93 was sufficient to decrease both JNK and p38 MAPK activation. In addition, an interesting observation is that the dual inhibition of JNK and p38 MAPK appears to contribute to the beneficial effects of DiOHF treatment. Thus an outstanding question remains regarding the mechanism through which myocardial CaMKII activates SAPKs and whether a common mechanism links CaMKII with JNK and p38 MAPK pathways. Active CaMKII has been shown previously to directly target ASK1, a MAPKKK capable of dual activation of JNK and 38 MAPK pathways [21, 59] . ASK1 has well-defined pro-apoptotic functions in vivo and in isolated cardiac mycoytes [60] . Furthermore, CaMKII activation of ASK1 is pro-apoptotic in spinal astrocytes [61] . Therefore it is likely that this mechanism is conserved in the heart although further studies will be required to demonstrate this.
In summary, our studies highlight the potent cytoprotective and cardioprotective actions of DiOHF. In characterizing the mechanism of action, we discovered DiOHF inhibition of CaMKII that is involved in signalling to downstream SAPKs. Importantly, our studies suggest that CaMKII-mediated p38 MAPK and JNK activation is detrimental in the context of cellular stress and I/R injury. These mechanistic findings highlight the potential therapeutic benefits of attenuating CaMKII signalling to SAPKs during myocardial I/R.
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